DiaMedica to Present at 16th Annual BIO CEO & Investor Conference
06 2월 2014 - 2:15AM
Marketwired
DiaMedica to Present at 16th Annual BIO CEO & Investor
Conference
MINNEAPOLIS, MINNESOTA--(Marketwired - Feb 5, 2014) - DiaMedica
(TSX-VENTURE:DMA), a clinical stage biopharmaceutical company,
announced today that Mr. Rick Pauls, Chief Executive Officer, will
provide a overview of the Company at the 16th annual BIO-CEO &
Investor conference on Tuesday February 11, 2014 at 3:00 pm EST, at
the Waldorf Astoria Hotel in New York. The conference is hosted by
the Biotechnology Industry Organization and is the largest
independent investor conference focused on established and emerging
publicly traded and select private biotech companies.
About DiaMedica
DiaMedica Inc. is a publicly traded (TSX-VENTURE:DMA) clinical
stage biopharmaceutical company focused on the discovery and
development of novel therapies to treat diabetes and the
complications associated with diabetes. DiaMedica's lead clinical
stage compound, DM199, is a recombinant human protein known as
rhKLK1 that represents a novel approach to treating diabetes and
associated complications. DiaMedica is also developing a novel
monoclonal antibody, DM204 for the treatment of Type 2 diabetes,
which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada
under the trading symbol 'DMA'.
FORWARD-LOOKING STATEMENTS
The statements made in this press release that are not
historical facts contain forward-looking information that involves
risk and uncertainties. All statements, other than statements of
historical facts, which address DiaMedica's expectations, should be
considered forward-looking statements. Such statements are based on
management's exercise of business judgment as well as assumptions
made by and information currently available to management. When
used in this document, the words "may", "will", "anticipate",
"believe", "estimate", "expect", "intend" and words of similar
import, are intended to identify any forward-looking statements.
You should not place undue reliance on these forward-looking
statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as
contained in the Corporation's filings with Canadian securities
regulatory authorities. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation
undertakes no obligation, and does not intend, to update, revise or
otherwise publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date
hereof, or to reflect the occurrence of any unanticipated events.
Although management believes that expectations are based on
reasonable assumptions, no assurance can be given that these
expectations will materialize.
Rick PaulsChairman & CEODiaMedica Inc.One Carlson Parkway,
Suite 124 , Minneapolis, MNPhone:
763-710-4455info@diamedica.com
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
DiaMedica Inc. (TSXV:DMA)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024